ESMO 2021 Prostate Cancer - Results from #60

Viewing 61-74 of 74 articles

ESMO 2021: TALAPRO-1: Talazoparib Monotherapy in Metastatic Castration-Resistant Prostate Cancer With DNA Damage Response Alterations—Exploration of Non-DDR Mutational Landscape and Potential Associations With Antitumor Activity

ESMO 2021: Safety of Tazemetostat in Combination With Abiraterone/Prednisone or Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

ESMO 2021: Patient-Reported Pain in Men With Metastatic Castration-Resistant Prostate Cancer Receiving Talazoparib: TALAPRO-1

ESMO 2021: Objective Computerized Cognitive Assessment in Men with Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Randomly Receiving Darolutamide or Enzalutamide in the ODENZA Trial

ESMO 2021: Pain Efficacy With Radium-223 in the REASSURE Global, Prospective, Observational Study of Men With Metastatic Castration-Resistant Prostate Cancer

ESMO 2021: Clinical and Cost Impact of Cabazitaxel vs a Second Androgen Receptor Targeted Agent for Patients With mCRPC Previously Treated With Docetaxel and the Alternative ARTA (Abiraterone or Enzalutamide)

ESMO 2021: PRORADIUM: Prospective Analysis of the Impact of Germline Mutations in Homologous Recombination Genes on the Response to Radium-223 for Metastatic Castration Resistant Prostate Cancer

ESMO 2021: Health-Related Quality of Life at Final Analysis of the GALAHAD Study of Niraparib in Patients With Metastatic Castration-Resistant Prostate Cancer and DNA Repair Defects

ESMO 2021: Bipolar Androgen Therapy (BAT) Plus Olaparib in Men With Metastatic Castration-Resistant Prostate Cancer

ESMO 2021: Comparing 177Lu-PSMA-617 Treatment with Androgen Receptor Pathway Inhibitor Switch in Taxane-Naïve mCRPC: Findings from the PSMAfore Phase 3 Study

ESMO 2021: Safety Analysis of the Phase III IPATential150 Trial of Ipatasertib plus Abiraterone in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

ESMO 2021: Final Results of Phase I/II Trial of Fractionated Dose 177Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

ESMO 2021: PSMAddition: A Phase 3 Trial to Compare Treatment with 177Lu-PSMA-617 plus Standard of Care (SOC) Versus SOC Alone in Patients with Metastatic Hormone-Sensitive Prostate Cancer

ESMO 2021: Androgen Changes After Enzalutamide or Abiraterone plus Prednisone in Men with Castration-Resistant Prostate Cancer (HEAT): Results from a Randomised Clinical Trial

1
2
3
4